BR112017013545A2 - composto de tiotriazol e seu uso em infecções por protozoários parasíticos - Google Patents

composto de tiotriazol e seu uso em infecções por protozoários parasíticos

Info

Publication number
BR112017013545A2
BR112017013545A2 BR112017013545A BR112017013545A BR112017013545A2 BR 112017013545 A2 BR112017013545 A2 BR 112017013545A2 BR 112017013545 A BR112017013545 A BR 112017013545A BR 112017013545 A BR112017013545 A BR 112017013545A BR 112017013545 A2 BR112017013545 A2 BR 112017013545A2
Authority
BR
Brazil
Prior art keywords
compound
thiotriazole
protozoan infections
parasitic protozoan
infections
Prior art date
Application number
BR112017013545A
Other languages
English (en)
Inventor
Diaz Hernandez Beatriz
Matthew Wilson David
Pilar Fernandez Velando Esther
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017013545A2 publication Critical patent/BR112017013545A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a um composto da fórmula (i) ou tautômeros deste tendo atividade farmacológica, processos para sua preparação, composições farmacêuticas e seu uso no tratamento de certas infecções por protozoários parasíticos tais como malária, em particular infecção por plasmodium falciparum. (i) (r)-2-((3-(3,5-dicloropiridin-4-il)-1h-1,2,4-triazol-5-il)tio)-1-(1h-indol-3-il)propan-1-ona.
BR112017013545A 2014-12-22 2015-12-21 composto de tiotriazol e seu uso em infecções por protozoários parasíticos BR112017013545A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382555 2014-12-22
PCT/EP2015/080730 WO2016102431A1 (en) 2014-12-22 2015-12-21 Thiotriazole compound and its use in parasitic protozoal infections

Publications (1)

Publication Number Publication Date
BR112017013545A2 true BR112017013545A2 (pt) 2018-03-06

Family

ID=52146396

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013545A BR112017013545A2 (pt) 2014-12-22 2015-12-21 composto de tiotriazol e seu uso em infecções por protozoários parasíticos

Country Status (16)

Country Link
US (1) US20170368034A1 (pt)
EP (1) EP3237400A1 (pt)
JP (1) JP2017538776A (pt)
KR (1) KR20170097051A (pt)
CN (1) CN107108572A (pt)
AR (1) AR103219A1 (pt)
AU (1) AU2015371169A1 (pt)
BR (1) BR112017013545A2 (pt)
CA (1) CA2971668A1 (pt)
PE (1) PE20171081A1 (pt)
PH (1) PH12017501072A1 (pt)
RU (1) RU2017126044A (pt)
SG (1) SG11201704584RA (pt)
TW (1) TW201636340A (pt)
UY (1) UY36469A (pt)
WO (1) WO2016102431A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210780A1 (es) * 2018-06-19 2021-04-21 Novartis Ag Compuestos de cianotriazol y usos de los mismos
EP4075980A4 (en) * 2019-12-18 2023-10-11 Stinginn LLC SUBSTITUTED 1,2,4-TRIAZOLES AND METHOD FOR USE THEREOF

Also Published As

Publication number Publication date
US20170368034A1 (en) 2017-12-28
WO2016102431A1 (en) 2016-06-30
UY36469A (es) 2016-06-30
TW201636340A (zh) 2016-10-16
SG11201704584RA (en) 2017-07-28
PE20171081A1 (es) 2017-08-03
RU2017126044A (ru) 2019-01-24
AU2015371169A1 (en) 2017-06-29
CN107108572A (zh) 2017-08-29
CA2971668A1 (en) 2016-06-30
PH12017501072A1 (en) 2017-11-27
EP3237400A1 (en) 2017-11-01
AR103219A1 (es) 2017-04-26
JP2017538776A (ja) 2017-12-28
KR20170097051A (ko) 2017-08-25

Similar Documents

Publication Publication Date Title
MD3377488T2 (ro) Compuși heterociclici ca imunomodulatori
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2015000880A1 (es) Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
MA32316B1 (fr) Derives spiro-indoles pour le traitement de maladies parasitaires
CA3010327A1 (en) Aryl substituted pyrimidines for use in influenza virus infection
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
BR112015019412A2 (pt) inibidores de bace1
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
BR112018074985A2 (pt) composições antibacterianas
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CL2018002074A1 (es) Composiciones y métodos para tratar infecciones.
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]